Predict your next investment

Corporation
HEALTHCARE | Disease Diagnosis
grail.com

See what CB Insights has to offer

Founded Year

2015

Stage

Acquired | Acquired

Total Raised

$2.005B

Valuation

$0000 

About GRAIL

GRAIL combines high-intensity sequencing, computer science, and large population-scale clinical studies to develop a blood test for early-stage cancer detection.On September 21st, 2020, GRAIL was acquired by Illumina at a valuation of $8B. At the time of the acquisition, Illumina, a prior investor in Grail owned 14.5% of the company’s outstanding shares which made the effective purchase price for Grail closer to $7 billion.

GRAIL Headquarter Location

1525 O'Brien Drive

Menlo Park, California, 94025,

United States

650-542-0372

Latest GRAIL News

Illumina (ILMN) Stock: $437 Price Target From Baird

Nov 25, 2021

The shares of Illumina, Inc. (NASDAQ: ILMN) have received a price target of $437 from Baird. These are the details. The shares of Illumina, Inc. (NASDAQ: ILMN) have received a price target of $437 from Baird. And Baird analyst Catherine Schulte reduced the price target on Illumina from $493 while maintaining a “Neutral” rating on the company shares. Schulte noted that the company’s third-quarter revenues were ahead of consensus, which was driven by record clinical and research sequencing shipments, population genomics initiatives, and better-than-expected COVID surveillance contributions. And Schulte is encouraged by what seems to be a healthy underlying demand. But she worries about some tough comps heading into next year. These are the highlights from the company’s Q3: — Revenue of $1,108 million, a 40% increase compared to the prior-year period — GAAP net income for the quarter of $317 million, or $2.08 per diluted share, which included a $900 million gain from our previously held investment in GRAIL and $654 million in day one compensation expense related to the GRAIL acquisition. This compared to $179 million, or $1.21 per diluted share, for the prior-year period — Non-GAAP net income for the quarter of $221 million, or $1.45 per diluted share, which included dilution from GRAIL non-GAAP operating loss of $0.19 per diluted share and incremental dilution from the 9.8 million shares issued to fund the GRAIL acquisition of $0.06 per diluted share. And this compared to $150 million, or $1.02 per diluted share, for the prior-year period. The non-GAAP net income excludes gain on a previously held investment in GRAIL, day one compensation-related expense and other acquisition-related expenses. — Cash flow from operations of $(272) million compared to $153 million in the prior-year period — Free cash flow (cash flow from operations less capital expenditures) of $(324) million for the quarter compared to $105 million in the prior year period Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing GRAIL

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

GRAIL is included in 6 Expert Collections, including Digital Health.

D

Digital Health

11,414 items

Startups recreating how healthcare is delivered

D

Digital Health 150

300 items

2019's cohort of the most promising digital health startups transforming the healthcare industry

C

Cancer

3,710 items

Products/services that analyze tumor-derived biomarkers (ctDNA, CTCs, exosomes) in blood/urine/other non-invasive liquid specimens to detect cancer earlier, guide treatment, and monitor progress. *Data fields manually updated as new information becomes available.'

M

Medical Devices

8,563 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health Monitoring & Diagnostics

2,394 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance

O

Omics

1,029 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

GRAIL Patents

GRAIL has filed 91 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • DNA
  • Genetics
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/31/2018

11/23/2021

Molecular biology, DNA, Biotechnology, Genetics, Molecular biology techniques

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

10/31/2018

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

11/23/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Molecular biology, DNA, Biotechnology, Genetics, Molecular biology techniques

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

GRAIL Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

GRAIL Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.